Expanded buybacks and executive purchases — GSK price forecast slips 1.57%

Traders Union
All News
Financial News
GSK slips 1.57% to GBX 1,782.00

Highlights

GSK senior executives recently acquired company shares under a reward plan, with director shareholding updates also disclosed alongside these purchases.
GSK expanded its ongoing share buyback program, purchasing over 17 million shares on November 12 and 13, 2025, increasing treasury shares to 256 million (6.31% of voting rights).
GSK established a partnership with AN2 Therapeutics targeting tuberculosis treatment, and provided block listing and updates on its own share transactions.

Executive share buys and new partnership drive sentiment shift

GSK disclosed recent share acquisitions by multiple senior executives under a reward plan, accompanied by updates on director shareholdings. The company expanded its ongoing share buyback program, with purchases totaling over 17 million shares on November 12 and November 13, 2025, raising treasury shares to more than 256 million, now representing 6.31% of total voting rights. Additionally, GSK formed a new partnership with AN2 Therapeutics focused on a tuberculosis treatment and provided a block listing and updates on transactions in its own shares.

Overbought signals diverge from firm momentum amid rising volatility

Momentum signals are mixed on the daily timeframe, with MACD and ADX both pointing to continued buying interest but several oscillators, notably the Stoch RSI and CCI, indicating overbought or mixed conditions. Bull/Bear Power (BBP) suggests the market is tilting toward overbought, even as the Awesome Oscillator remains neutral. The nearest dynamic support sits at the Ichimoku Kijun line (GBX 1,713.25), while resistance is found near the MA-5 (GBX 1,799.80). Volatility has been moderate, and price action shows signs of pressure after the open. This intraday weakness is not fully confirmed by momentum indicators, which reveals divergence with daily oscillators.

High upside probability as price consolidates near resistance

For the next five trading days, the expected range is normalized to GBX 1,760.00 – 1,800.00, bracketing the current price. The probability of a meaningful price increase is very high (more than 80%), with a drop being less likely. In the baseline scenario, the price holds in a sideways corridor between support at GBX 1,760.00 and resistance at GBX 1,800.00. A bullish scenario will see a breakout above GBX 1,800.00 toward new short-term highs, while failure of support at GBX 1,760.00 could lead to a pullback to the Ichimoku Kijun at GBX 1,713.25.

Anton Kharitonov, analyst at Traders Union, sees GSK maintaining a bullish structure on higher timeframes, but notes growing intraday weakness. He points to persistent buying interest and news of insider accumulation, yet highlights overbought signals and potential pullback risks if support is lost. Kharitonov remains defensively positioned, citing divergence between momentum and oscillators. "Base case remains for sideways action between GBX 1,760.00 and GBX 1,800.00 — if support at GBX 1,760.00 fails, expect a deeper correction toward GBX 1,713.25."

Last time, it was noted that GSK continued its share buyback activity and formed a partnership with AN2 Therapeutics to advance tuberculosis drug development. Technical analysis highlighted overbought momentum alongside robust trend strength, as discussed in overbought momentum alongside robust trend.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.